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HIV drug resistance has proved to one of the greatest
challenges to effective and durable viral suppression.
Selection of drug resistance mutations and widespread
cross-resistance between agents of a class are a main
obstacle when administering antiretroviral agents in
clinical practice. This has been perhaps the greatest bar-
rier to incorporating HIV care in to routine medical
management administered by general practitioners. As
opposed to many other disease states where the devel-
opment of effective therapy allowed for simple wide-
spread use as part of general care, HIV drug resistance
has mandated cumbersome, resource consuming and
demanding medical practice from both clinicians and
even more so patients. Extremely demanding lifelong
drug taking behavior by patients, high level clinician
knowledge and expertise; and expensive monitoring
technologies are all required for durable clinical benefit
from antiretroviral therapy due to resistance.
But knowledge and understanding of drug resistance
has also brought great improvement in HIV care. Tech-
nologies to detect and identify resistance as well as
rapid and reasonably accurate interpretation have been
developed and refined. A far greater understanding of
resistance and its consequences by providers and
patients have molded our highly effective modern care.
Development of improved drugs including those with
unique mechanisms has greatly benefited from our
growing knowledge.
As we move forward to the next decade of HIV care,
we need to revisit how we relate to and address HIV
drug resistance. Old assumptions need to be challenged;
data needs to be critically evaluated considering our
new and improved drugs, and widespread treatment of
patients in resource limited settings need to be
specifically prioritized as challenges may not be identi-
cal. How should our much improved (but expensive)
resistance assays be used? To what degree do we need
to continue to closely monitor HIV drug resistance and
in what settings? Is resistance still a high priority when
designing optimal drug combinations for our patients –
those naive and those drug-experienced? How can we
minimize the barrier resistance presents to more simpli-
fied and widespread antiretroviral therapy? These are
important issues we must address to guarantee the best
care for the most patients in coming years.
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